ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2019
Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study.
Open access · goldAbstract read
In one paragraph
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Subjective Cognitive Concerns and Cognitive Trajectories in Parkinson's Disease: Biomarker Impact.Annals of clinical and translational neurology · 2026Article
- Risk factors and cognitive domain markers of progression in subjective cognitive decline.Journal of Alzheimer's disease : JAD · 2026Article
- Metacognition and metacognitive monitoring in aging.Psychonomic bulletin & review · 2026Review
- Migraine and menopause as converging factors in brain vulnerability: a hypothesis-driven perspective.The journal of headache and pain · 2026Review
- Evaluating sex and gender as separate and interactive predictors of memory aging trajectory classes: an integrative data-driven approach.Biology of sex differences · 2026Article
- PTSD moderates the association between subjective cognitive decline and Alzheimer's disease biomarkers in older veterans.Aging & mental health · 2025Article
- Differential Item Functioning and Clinical Utility of the Subjective Memory Complaints Questionnaire in a Multi-Ethnic Cohort.Dementia and geriatric cognitive disorders · 2025Article
- Self- and study partner-reported cognitive decline in older adults without dementia: The role of α-synuclein and amyloid biomarkers in the Alzheimer's Disease Neuroimaging Initiative.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Identifying longitudinal cognitive resilience from cross-sectional amyloid, tau, and neurodegeneration.Alzheimer's research & therapy · 2024Article
- The characteristic pattern of functional connectivity density influenced by postmenopausal females in the preclinical stage of dementia.Cerebral cortex (New York, N.Y. : 1991) · 2024Article
- Detecting cognitive decline in high-functioning older adults: The relationship between subjective cognitive concerns, frequency of high neuropsychological test scores, and the frontoparietal control network.Journal of the International Neuropsychological Society : JINS · 2024Article
- Subjective cognitive and olfactory impairments predict different prospective dementia outcomes.Chemical senses · 2024Article
- Predicting amyloid-beta pathology in the general population.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive Decline.Neurology · 2023Observational
- Low thalamic activity during a digit-symbol substitution task is associated with symptoms of subjective cognitive decline.Frontiers in psychiatry · 2023Article
- Characteristics of subjective cognitive decline associated with amyloid positivity.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint.Alzheimer's research & therapy · 2022Article
- Subjective Cognitive Decline and its Relation to Verbal Memory and Sex in Cognitively Unimpaired Individuals from a Colombian Cohort with Autosomal-Dominant Alzheimer's Disease.Journal of the International Neuropsychological Society : JINS · 2022Article
- Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD): A Report of an International Research Collaboration Network.Journal of Alzheimer's disease : JAD · 2022Review
- Detection of β-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers.Brain communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 3 countries.
Rachel F BuckleyThe Florey Institute, The University of Melbourne, Melbourne, Victoria, Australia.
Sietske SikkesAlzheimer Center and Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, the Netherlands.
Victor L VillemagneDepartment of Nuclear Medicine and Centre for PET, Austin Health, Victoria, Australia.
Elizabeth C MorminoDepartment of Neurology, Stanford University, Palo Alto, CA, USA.
Jennifer S RabinDepartment of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Samantha BurnhamDepartment of Nuclear Medicine and Centre for PET, Austin Health, Victoria, Australia.
Kathryn V PappDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Vincent DoréDepartment of Nuclear Medicine and Centre for PET, Austin Health, Victoria, Australia.
Colin L MastersThe Florey Institute, The University of Melbourne, Melbourne, Victoria, Australia.
Michael J ProperziDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Aaron P SchultzDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Keith A JohnsonCenter for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
Dorene M RentzDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Reisa A SperlingDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Rebecca E AmariglioDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Harvard University · USMassachusetts General Hospital · USBrigham and Women's Hospital · USUniversity of Melbourne · AUAmsterdam University Medical Centers · NLAustin Health · AUCSIRO Health and Biosecurity · AUStanford University · US
Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MRECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6MVascular factors, physical activity, and inflammation as modulators of neurodegenerative and cognitive trajectories (Project 2)P01AG036694 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Frances Buckley, Keith A. Johnson · 2010 to 2026
$50.2MTHE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 1985 to 2018
$42.1MResearch Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI MATTHEW P FROSCH · 2019 to 2026
$36.5MProject 4P41EB015896 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI ROSEN, BRUCE R · 2012 to 2018
$9.8MEvolution of memory-related fMRI activation over the course of MCI and ADR01AG027435 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI JOHNSON, KEITH A., SPERLING, REISA A. · 2006 to 2016
$8.6MVascular Dysfunction in Cerebral Amyloid AngiopathyR01AG026484 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI GREENBERG, STEVEN M · 2005 to 2019
$7.5MImaging CoreU01AG032438 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2008 to 2009
$6.1MCharacterizing the Evolution of Amyloid Deposition in Normal ElderlyR01AG037497 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI JOHNSON, KEITH A. · 2010 to 2014
$3.2MNeural Processes Underlying Cognitive AgingR01AG034556 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI BUCKNER, RANDY L · 2009 to 2013
$2.7MMR-assisted PET data optimization for neuroimaging studiesR01EB014894 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI CATANA, CIPRIAN · 2013 to 2016
$2.6MNCRR NIH HHS S10 RR021110NCRR NIH HHS S10 RR023043NCRR NIH HHS S10 RR023401NIA NIH HHS K01 AG051718NIA NIH HHS K23 AG049087NIA NIH HHS K24 AG035007NIA NIH HHS K99 AG061238NIA NIH HHS P01 AG036694NIA NIH HHS P30 AG062421NIA NIH HHS P50 AG005134NIA NIH HHS R01 AG026484NIA NIH HHS R01 AG027435NIA NIH HHS R01 AG034556NIA NIH HHS R01 AG037497NIA NIH HHS R21 AG038994NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG032438NIA NIH HHS U19 AG010483NIBIB NIH HHS K23 EB019023NIBIB NIH HHS P41 EB015896NIBIB NIH HHS R01 EB014894
Abstract
introductionWe aimed to examine the contribution of subjective cognitive decline (SCD) to reduce the number of β-amyloid (Aβ) positron emission tomography scans required for recruiting Aβ+ clinically normal individuals in clinical trials.
methodsThree independent cohorts (890 clinically normal: 72 yrs ± 6.7; Female: 43.4%; SCD+: 24%; apolipoprotein E [
resultsSCD increased odds of Aβ+ by 1.58 relative to non-SCD. Female
conclusionSCD helps to classify those with high Aβ, even beyond the substantial effect of
Indexed as
Alzheimer's diseaseAmyloidAPOEε4Subjective cognitive decline
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.